{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T03:20:34Z","timestamp":1764645634073,"version":"3.41.2"},"reference-count":56,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> The impact of nonalcoholic fatty liver disease (NAFLD) on overall survival (OS), treatment response and toxicity in patients with hepatocellular carcinoma (HCC) treated with sorafenib is unknown. We examined the impact of NAFLD on survival and toxicity in an international cohort of patients receiving sorafenib. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> Clinical and demographic data were collected from patients consecutively treated at specialist centres in Europe and North America. The impact of NAFLD on OS, sorafenib-specific survival and toxicity compared with other aetiologies of liver disease using multivariable Cox-proportional hazards and logistic regression modelling was assessed. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> A total of 5201 patients received sorafenib; 183 (3.6%) had NAFLD-associated HCC. NAFLD-associated HCC patients were more likely to be older women (median age 65.8 versus 63.0\u2009years, p\u2009&lt;\u20090.01 and 10.4% versus 2.3%,\u2009&lt;\u20090.01), with a median body mass index (BMI) of 29.4. After controlling for known prognostic factors, no difference in OS in patients with or without NAFLD was observed [hazard ratio (HR): 0.99, 95% confidence interval (CI): 0.84\u20131.18, p\u2009=\u20090.98]. NAFLD-associated patients had more advanced stage HCC when they commenced sorafenib [Barcelona Clinic Liver Class (BCLC) C\/D 70.9% versus 58.9%, p\u2009&lt;\u20090.01] and were more likely to be commenced on a lower starting dose of sorafenib (51.4 versus 36.4%, p\u2009&lt;\u20090.01). There was no difference in sorafenib-specific survival between NAFLD and other aetiologies (HR: 0.96, 95% CI: 0.79\u20131.17, p\u2009=\u20090.96). Adverse events were similar between NAFLD and non-NAFLD HCC groups, including rates of greater than grade 2 hypertension (6.3% versus 5.8%, p\u2009=\u20091.00). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p> Survival in HCC does not appear to be influenced by the presence of NAFLD. NAFLD-associated HCC derive similar clinical benefit from sorafenib compared with other aetiologies. <\/jats:p><\/jats:sec>","DOI":"10.1177\/17562848221100106","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T10:40:40Z","timestamp":1664534440000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study"],"prefix":"10.1177","volume":"15","author":[{"given":"Jessica","family":"Howell","sequence":"first","affiliation":[{"name":"Department of Medicine, The University of Melbourne, St Vincent\u2019s Hospital, Melbourne, VIC, Australia"},{"name":"Disease Elimination Program, Macfarlane-Burnet Institute, Melbourne, VIC, Australia"},{"name":"Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Samani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hammersmith Hospital, Imperial College Hospital NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binish","family":"Mannan","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saur","family":"Hajiev","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Motedayen Aval","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Abdelmalak","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent C.","family":"Tam","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Bettinger","sequence":"additional","affiliation":[{"name":"University Medical Center Freiburg and Department of Medicine II, University of Freiburg, Freiburg, Germany"},{"name":"Berta-Ottenstein Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Thimme","sequence":"additional","affiliation":[{"name":"University Medical Center Freiburg and Department of Medicine II, University of Freiburg, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar H.","family":"Taddei","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, CT, USA; VA Connecticut Healthcare System, West Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Seidensticker","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Radiologie, Klinikum der Universit\u00e4t M\u00fcnchen, LMU M\u00fcnchen, Munchen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2441-549X","authenticated-orcid":false,"given":"Rohini","family":"Sharma","sequence":"additional","affiliation":[{"name":"Consultant and Reader in Medical Oncology and Clinical Pharmacology, Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"bibr1-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31937"},{"key":"bibr2-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27222"},{"key":"bibr3-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3055"},{"key":"bibr4-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-018-0812-z"},{"key":"bibr5-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.011"},{"key":"bibr6-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.109"},{"key":"bibr7-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.05.036"},{"key":"bibr8-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"},{"key":"bibr9-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"bibr10-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30018-8"},{"key":"bibr11-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28368"},{"key":"bibr12-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.10.001"},{"key":"bibr13-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.08.011"},{"key":"bibr14-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.08.024"},{"key":"bibr15-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14342"},{"key":"bibr16-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"bibr17-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"bibr18-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.5197"},{"key":"bibr19-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.06.014"},{"key":"bibr20-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67402-8"},{"key":"bibr21-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1177\/1074248416686187"},{"key":"bibr22-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.005"},{"key":"bibr23-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04724.x"},{"key":"bibr24-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.1291"},{"key":"bibr25-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.330"},{"key":"bibr26-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.34168"},{"key":"bibr27-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.02.063"},{"key":"bibr28-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0145-7"},{"key":"bibr29-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"bibr30-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz394.029"},{"key":"bibr31-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.8245"},{"key":"bibr32-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1159\/000490260"},{"key":"bibr33-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy149.028"},{"key":"bibr34-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.006"},{"key":"bibr35-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.04.008"},{"key":"bibr36-17562848221100106","doi-asserted-by":"publisher","DOI":"10.4158\/EP15693.CS"},{"key":"bibr37-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01260-w"},{"key":"bibr38-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60892-8"},{"key":"bibr39-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60813-1"},{"key":"bibr40-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-008-2262-x"},{"key":"bibr41-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.327"},{"key":"bibr42-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26986"},{"key":"bibr43-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28123"},{"key":"bibr44-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.08.013"},{"key":"bibr45-17562848221100106","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i4.1189"},{"key":"bibr46-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-011-0431-9"},{"key":"bibr47-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1159\/000501484"},{"key":"bibr48-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.012"},{"key":"bibr49-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"bibr50-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.09.031"},{"key":"bibr51-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.08.015"},{"key":"bibr52-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30270-X"},{"key":"bibr53-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039"},{"key":"bibr54-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1038\/nature16969"},{"key":"bibr55-17562848221100106","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.09.031"},{"key":"bibr56-17562848221100106","unstructured":"NHS England Cancer Drugs Fund Team. National Cancer Drugs Fund list. London: NHS England, 2020, pp. 1\u2013174."}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848221100106","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848221100106","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848221100106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T04:15:05Z","timestamp":1740802505000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848221100106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":56,"alternative-id":["10.1177\/17562848221100106"],"URL":"https:\/\/doi.org\/10.1177\/17562848221100106","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"type":"print","value":"1756-2848"},{"type":"electronic","value":"1756-2848"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"17562848221100106"}}